The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
- PMID: 32673741
- DOI: 10.1016/j.jhep.2020.06.013
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
Abstract
Background & aims: Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF.
Methods: A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded.
Results: Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC).
Conclusions: Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS.
Gov number: NCT03056612.
Lay summary: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.
Keywords: Acute complications; Chronic liver disease; Non-elective admission; Outcome; Risk factors.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest None of the authors have conflicts of interest for the reported study. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Predicting development of ACLF.Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):531. doi: 10.1038/s41575-020-0355-z. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32759982 No abstract available.
-
Acute-on-chronic liver failure: The challenge of PREDICTing who and when.J Hepatol. 2020 Oct;73(4):755-756. doi: 10.1016/j.jhep.2020.07.029. Epub 2020 Aug 13. J Hepatol. 2020. PMID: 32800351 No abstract available.
-
Pre-acute-on-chronic liver failure in hepatitis B-related patients.J Hepatol. 2021 Feb;74(2):479-480. doi: 10.1016/j.jhep.2020.09.001. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33279256 No abstract available.
-
Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.J Hepatol. 2021 Feb;74(2):480-481. doi: 10.1016/j.jhep.2020.11.012. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33279257 No abstract available.
-
PREDICTing acute-on-chronic liver failure in patients with acute decompensation.J Hepatol. 2021 Feb;74(2):478-479. doi: 10.1016/j.jhep.2020.08.031. Epub 2020 Dec 3. J Hepatol. 2021. PMID: 33279258 No abstract available.
Similar articles
-
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study.Liver Int. 2024 Jan;44(1):72-82. doi: 10.1111/liv.15734. Epub 2023 Sep 18. Liver Int. 2024. PMID: 37718730
-
Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis.JHEP Rep. 2022 Jul 5;4(10):100529. doi: 10.1016/j.jhepr.2022.100529. eCollection 2022 Oct. JHEP Rep. 2022. PMID: 36052222 Free PMC article.
-
Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.United European Gastroenterol J. 2021 May;9(4):427-437. doi: 10.1002/ueg2.12089. United European Gastroenterol J. 2021. PMID: 34050619 Free PMC article.
-
Acute-on-chronic liver failure in cirrhosis.Nat Rev Dis Primers. 2016 Jun 9;2:16041. doi: 10.1038/nrdp.2016.41. Nat Rev Dis Primers. 2016. PMID: 27277335 Review.
-
Prognostic assessment of liver cirrhosis and its complications: current concepts and future perspectives.Front Med (Lausanne). 2023 Sep 14;10:1268102. doi: 10.3389/fmed.2023.1268102. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37780566 Free PMC article. Review.
Cited by
-
Bacterial Infection Features in Alcohol-Associated Hepatitis: Review of a 2016-2021 Cohort.J Clin Med. 2024 Sep 25;13(19):5693. doi: 10.3390/jcm13195693. J Clin Med. 2024. PMID: 39407753 Free PMC article.
-
Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial.Trials. 2022 Mar 18;23(1):222. doi: 10.1186/s13063-022-06139-6. Trials. 2022. PMID: 35303938 Free PMC article. Clinical Trial.
-
Exaggerated inflammatory response to bacterial products in decompensated cirrhotic patients is orchestrated by interferons IL-6 and IL-8.Am J Physiol Gastrointest Liver Physiol. 2022 May 1;322(5):G489-G499. doi: 10.1152/ajpgi.00012.2022. Epub 2022 Feb 23. Am J Physiol Gastrointest Liver Physiol. 2022. PMID: 35195033 Free PMC article.
-
Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis.Hepatol Int. 2023 Jun;17(3):698-708. doi: 10.1007/s12072-022-10473-x. Epub 2023 Jan 18. Hepatol Int. 2023. PMID: 36652164 Free PMC article.
-
Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease.Gut Liver. 2024 Jan 15;18(1):27-39. doi: 10.5009/gnl230072. Epub 2023 Oct 16. Gut Liver. 2024. PMID: 37842727 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical